Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 1 Hba1c.
Figuras y tablas -
Analysis 1.1

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 1 Hba1c.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 2 Hba1c by different types of interventions: CSII,. IIT.
Figuras y tablas -
Analysis 1.2

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 2 Hba1c by different types of interventions: CSII,. IIT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 3 Hba1c by duration of study: less than or equal to 3 months, more than 3 months.
Figuras y tablas -
Analysis 1.3

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 3 Hba1c by duration of study: less than or equal to 3 months, more than 3 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 4 Hba1c by different short acting insulin analogues: Lispro, Aspart.
Figuras y tablas -
Analysis 1.4

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 4 Hba1c by different short acting insulin analogues: Lispro, Aspart.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 5 Hba1c by different types of study design: parallel, cross‐over studies.
Figuras y tablas -
Analysis 1.5

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 5 Hba1c by different types of study design: parallel, cross‐over studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 6 Hypoglycaemic episodes.
Figuras y tablas -
Analysis 1.6

Comparison 1 Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 6 Hypoglycaemic episodes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 1 Hba1c.
Figuras y tablas -
Analysis 2.1

Comparison 2 Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 1 Hba1c.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 2 Hypoglycaemic episodes.
Figuras y tablas -
Analysis 2.2

Comparison 2 Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin, Outcome 2 Hypoglycaemic episodes.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Quality of life and treatment satisfaction

Trial

Diabetes

Method

Outcome

Kotsanos 1997

type 1

DQLCTQ

improvement in 3 of 34 domains in favour of analogue

Holleman 1997

type 1

PEQ

improvement in favour of analogue

Schmauss 1998

type 1

not reported

no difference

Johansson 1999

type 1

DTSQ, WBQ

no difference in both scores

Renner 1999

type 1

DTSQ

improvement in favour of analogue

Gale 2000

type 1

DTSQ, WBQ

no difference in both scores

Home 2000

type 1

DTSQ

improvement in favour of analogue (UK‐centers)

Bott 2003

type 1

DTSQ, DSQoLS

improvement in favour of analogue (german speaking centers of Home 2000)

Ferguson 2001

type 1

DTSQ, HFS

no difference in both scores

Annuzzi 2001

type 1

DTSQ

improvement in subdomains in favour of analogue

Kotsanos 1997

type 2

DQLCTQ

no difference in any of the 34 domains

Ross 2001

type 2

DQOL

no difference
Figuras y tablas -
Table 1. Quality of life and treatment satisfaction
Ir a la tabla de la revisión
Table 2. Results of DTSQ (˜ no difference, + improvements in favor of analogue treatment)

DTSQ domains

Johansson 1999

Renner 1999

Gale 2000

Home 2000

Bott 2003

Ferguson 2001

Annuzzi 2001

Satisfaction with current treatment

˜

not reported

˜

˜

˜

˜

+

Unacceptably high blood sugar

˜

not reported

˜

˜

˜

˜

not reported

Unacceptably low blood sugar

˜

not reported

˜

˜

˜

˜

not reported

Convenience of treatment

˜

not reported

˜

+

+

˜

+

Flexibility of treatment

˜

not reported

˜

+

+

˜

+

Understanding of diabetes

˜

not reported

˜

˜

˜

˜

not reported

Recommendations of treatment

˜

not reported

˜

˜

+

˜

not reported

Continuation of treatment

˜

not reported

˜

+

+

˜

+

DTSQ TOTAL SCORE

˜

+

˜

+

+

˜

not reported

injection interval (min.): analogue vs. regular

5 vs. 30

i vs. 30

i vs. i

i vs. 30

i vs. 30

i vs. 30

i vs. 30
Figuras y tablas -
Table 2. Results of DTSQ (˜ no difference, + improvements in favor of analogue treatment)
Ir a la tabla de la revisión
Comparison 1. Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Hba1c Show forest plot

21

mean difference (Random, 95% CI)

‐0.12 [‐0.17, ‐0.07]

2 Hba1c by different types of interventions: CSII,. IIT Show forest plot

21

mean difference (Random, 95% CI)

‐0.12 [‐0.17, ‐0.07]

2.1 CSII

8

mean difference (Random, 95% CI)

‐0.19 [‐0.27, ‐0.12]

2.2 IIT

13

mean difference (Random, 95% CI)

‐0.08 [‐0.15, ‐0.02]

3 Hba1c by duration of study: less than or equal to 3 months, more than 3 months Show forest plot

21

mean difference (Random, 95% CI)

‐0.12 [‐0.17, ‐0.07]

3.1 <= 3 months

11

mean difference (Random, 95% CI)

‐0.09 [‐0.18, 0.00]

3.2 >3 months

10

mean difference (Random, 95% CI)

‐0.15 [‐0.21, ‐0.10]

4 Hba1c by different short acting insulin analogues: Lispro, Aspart Show forest plot

21

mean difference (Random, 95% CI)

‐0.12 [‐0.17, ‐0.07]

4.1 Lispro

16

mean difference (Random, 95% CI)

‐0.11 [‐0.18, ‐0.04]

4.2 Aspart

5

mean difference (Random, 95% CI)

‐0.15 [‐0.22, ‐0.07]

5 Hba1c by different types of study design: parallel, cross‐over studies Show forest plot

21

mean difference (Random, 95% CI)

‐0.12 [‐0.17, ‐0.07]

5.1 parallel studies

9

mean difference (Random, 95% CI)

‐0.15 [‐0.22, ‐0.08]

5.2 cross‐over studies

12

mean difference (Random, 95% CI)

‐0.11 [‐0.19, ‐0.03]

6 Hypoglycaemic episodes Show forest plot

11

3819

Mean Difference (IV, Random, 95% CI)

‐0.17 [‐1.20, 0.87]
Figuras y tablas -
Comparison 1. Type 1 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin
Ir a la tabla de la revisión
Comparison 2. Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Hba1c Show forest plot

4

mean difference (Random, 95% CI)

‐0.02 [‐0.10, 0.07]

2 Hypoglycaemic episodes Show forest plot

5

2617

Mean Difference (IV, Random, 95% CI)

‐0.17 [‐0.46, 0.12]
Figuras y tablas -
Comparison 2. Type 2 diabetic patients: short acting insulin anlogues versus structurally unchanged insulin
Ir a la tabla de la revisión